General MedicationsINTRAVENOUSStandard
REGADENOSON
REGADENOSON
Standard Dose
0.4MG/5ML (0.08MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview REGADENOSON is listed in Drugs@FDA under application 218054 (ANDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient REGADENOSON Form and strength SOLUTION;INTRAVENOUS - 0.4MG/5ML (0.08MG/ML) Sponsor INDIES PHARMA Submission history Latest submission status date: 2024-08-22 00:00:00.
Structured Monograph
Clinical summary
Approval overview REGADENOSON is listed in Drugs@FDA under application 218054 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient REGADENOSON Form and strength SOLUTION;INTRAVENOUS - 0.4MG/5ML (0.08MG/ML) Sponsor INDIES PHARMA Submission history Latest submission status date: 2024-08-22 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.